FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,396 | -59.1% | 50,187 | -8.1% | 0.00% | -66.7% |
| Q2 2023 | $259,948 | +86839.1% | 54,611 | +4.2% | 0.00% | -40.0% |
| Q1 2023 | $299 | -43.9% | 52,434 | -0.7% | 0.01% | -54.5% |
| Q4 2022 | $533 | -99.9% | 52,784 | +12.3% | 0.01% | -52.2% |
| Q3 2022 | $1,053,000 | +15.7% | 46,999 | +28.0% | 0.02% | -4.2% |
| Q2 2022 | $910,000 | +55.3% | 36,715 | +142.9% | 0.02% | +71.4% |
| Q1 2022 | $586,000 | -70.1% | 15,114 | -54.9% | 0.01% | -57.6% |
| Q4 2021 | $1,961,000 | +567.0% | 33,515 | +841.4% | 0.03% | +450.0% |
| Q1 2021 | $294,000 | -82.5% | 3,560 | -91.5% | 0.01% | -91.8% |
| Q3 2020 | $1,680,000 | +29.8% | 42,035 | +11.5% | 0.07% | +14.1% |
| Q2 2020 | $1,294,000 | +79.2% | 37,710 | -18.9% | 0.06% | +156.0% |
| Q3 2019 | $722,000 | – | 46,484 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |